Guanidino, thioureido and isothioureido derivatives containing imidazole groups

Abstract

The compounds are C 2 -C 8 straight chain alkanes terminally substituted, symmetrically or unsymmetrically, by N-(N'-substituted guanidino), N-(N', N"-disubstituted guanidino), N-(N'-substituted thiouredo), N-(nitromethylene amidino) or S-(N-substituted isothioureido) groups. Two compounds of the invention are 1,3-bis-[N'-(2-(5-methyl-4-imidazolylmethylthio)ethyl)guanidino]propane and 1,3-bis-[S-(N-2-(5-methyl-4-imidazolylmethylthio)ethyl)isothioureido]propane. The compounds of this invention are inhibitors of H-2 histamine receptors.

What is claimed is: 
     
       1. A compound of the formula: ##STR18## wherein R 1  and R 2 , which may be the same or different, each represent a grouping of the structure:   Het -- (CH.sub.2).sub.m Z -- (CH.sub.2).sub.n --     wherein Het is imidazole which is attached at a ring carbon and which is optionally substituted by lower alkyl or halogen; Z is sulphur or a methylene group; m is 0, 1 or 2; n is 2 or 3 and the sum of m and n is 3 .[.,.]. .Iadd.or .Iaddend.4 .[.or when the adjoining X 1  or X 2  is sulphur, 2.].; X 1  and X 2 , which may be the same or different, are each sulphur or NY wherein Y is hydrogen or lower alkyl; W is NH, and when X 1  and X 2  are NH, W may also be sulphur; and q is an integer from 2 to 8; or a pharmaceutically acceptable acid addition salt thereof.   
     
     
       2. A compound according to claim 1 wherein W is NH. 
     
     
       3. A compound according to claim 2 wherein X 1  and X 2 , which may be the same or different, are each sulphur or NY and wherein Y is defined in claim 1. 
     
     
       4. A compound according to claim 1 wherein R 1  and R 2  are the same. 
     
     
       5. A compound according to claim 1 wherein Z is sulphur, m is 1 and n is 2. 
     
     
       6. A compound according to claim 1 wherein Het is imidazole or imidazole substituted by methyl or halogen. 
     
     
       7. A compound according to claim 1 wherein X 1  and X 2  are the same. 
     
     
       8. A compound according to claim 7 wherein X 1  and X 2  are both sulphur or NH. 
     
     
       9. A compound according to claim 1 wherein q is from 2 to 4. 
     
     
       10. A compound according to claim 9 wherein q is 3. 
     
     
       11. A compound according to claim 1, said compound being 1,2-bis-[N'-[2-(5-methyl-4-imidazolylmethylthio)ethyl) thioureido]-ethane. 
     
     
       12. A compound according to claim 1, said compound being 1,3-bis-[N'-(2-(5-methyl-4-imidazolylmethylthio)ethyl) thioureido]-propane. 
     
     
       13. A compound according to claim 1, said compound being 1,4-bis-[N'-(2-(-5-methyl-4-imidazolylmethylthio)ethyl) thioureido]-butane. 
     
     
       14. A compound according to claim 1, said compound being 1,3-bis-[N'-(2-(5-methyl-4-imidazolylmethylthio)ethyl) guanidino]propane. 
     
     
       15. A compound according to claim 1, said compound being 1,3-bis-[S-(N-2-(5-methyl-4-imidazolylmethylthio)ethyl) isothioureido]propane. 
     
     
       16. A pharmaceutical composition to inhibit H-2-histamine receptors, said H-2 -histamine receptors, said H-2 histamine receptors being those histamine receptors which are not inhibited by mepyramine but are inhibited by burimamide, comprising, in an effective amount to inhibit H-2 histamine receptors, a compounds of claim 1 in combination with a pharmaceutically acceptable diluent or carrier. 
     
     
       17. A method of inhibiting H-2 histamine receptors, said H-2 histamine receptors being those histamine receptors which are not inhibited by mepyramine but are inhibited by burimamide, which comprises administering to an animal in need of inhibition of said H-2 histamine receptors in an effective amount to inhibit said H-2 histamine receptors a compound of claim 1. 
     
     
       18. A compound according to claim 1, said compound being 1,6-bis-[N'-(2-(5-methyl-4-imidazolylmethylthio)ethyl)-quanidino]hexane. 
     
     
       19. A compound according to claim 1, said compound being 1,8-bis-[N'-(2-(5-methyl-4-imidazolymethylthio)ethyl)-guanidino]octane.